Eczema Treatment Report

www.EczemaTreatmentReport.com

Clinical Trials

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis [Terminated]

https://clinicaltrials.gov/ct2/show/NCT03568071?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: MOR 106;   Drug: Placebo
Sponsor:   Galapagos NV
Terminated

CLINICALTRIALS.GOV IDENTIFIER:
NCT03568071

FIRST POSTED:
Tue, 26 Jun 2018 12:00:00 EDT

LAST UPDATE POSTED:
03/18/20 10:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03568071?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04313400?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: 1.1% w/w AMTX-100 CF;   Drug: 0.33% w/w AMTX-100 CF;   Drug: 0.11% w/w AMTX-100 CF;   Drug: Placebo
Sponsors:   Amytrx Therapeutics, Inc.;   Amarex Clinical Research
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04313400

FIRST POSTED:
Wed, 18 Mar 2020 12:00:00 EDT

LAST UPDATE POSTED:
03/18/20 10:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04313400?type=Intr&cond=Eczema&phase=0124&lupd_s=03%2F04%2F2020&lupd_d=14&sort=nwst

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

https://clinicaltrials.gov/ct2/show/NCT04135560?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

DESCRIPTION:
Condition:   Dermatitis Atopic
Interventions:   Drug: PF-07038124 and Vehicle;   Drug: PF-07038124 or vehicle
Sponsor:   Pfizer
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04135560

FIRST POSTED:
Tue, 22 Oct 2019 12:00:00 EDT

LAST UPDATE POSTED:
10/22/19 07:07AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04135560?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT03915496?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F07%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: PF-04965842 200 mg;   Drug: PF-04965842 100 mg;   Drug: Placebo
Sponsor:   Pfizer
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03915496

FIRST POSTED:
Tue, 16 Apr 2019 12:00:00 EDT

LAST UPDATE POSTED:
10/21/19 08:13AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03915496?type=Intr&cond=Eczema&phase=0124&lupd_s=10%2F07%2F2019&lupd_d=14&sort=nwst

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatiti

https://clinicaltrials.gov/ct2/show/NCT03568071?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F23%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: MOR 106;   Drug: Placebo
Sponsor:   Galapagos NV
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03568071

FIRST POSTED:
Mon, 25 Jun 2018 12:00:00 EDT

LAST UPDATE POSTED:
10/07/19 07:50AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03568071?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F23%2F2019&lupd_d=14&sort=nwst

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT03517566?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: Placebo;   Drug: ZPL389
Sponsor:   Novartis Pharmaceuticals
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03517566

FIRST POSTED:
Mon, 07 May 2018 12:00:00 EDT

LAST UPDATE POSTED:
10/01/19 07:03AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03517566?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst

A Phase I Clinical Study of Hemay808 in Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04100642?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F10%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase I Clinical Study of Hemay808

DESCRIPTION:
Condition:   Safety Issues
Interventions:   Drug: Hemay808;   Drug: Placebo
Sponsor:   Tianjin Hemay Pharmaceutical Co.,Ltd
Enrolling by invitation

CLINICALTRIALS.GOV IDENTIFIER:
NCT04100642

FIRST POSTED:
Tue, 24 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/24/19 06:52AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04100642?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F10%2F2019&lupd_d=14&sort=nwst

Phase 2 Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids in Adult Subjects With Moderate to Severe Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT03864627?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Test Safety and Tolerability of a Study Drug Called MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Patients With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: MOR106;   Drug: Placebo
Sponsor:   Galapagos NV
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03864627

FIRST POSTED:
Wed, 06 Mar 2019 12:00:00 EST

LAST UPDATE POSTED:
09/23/19 07:49AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03864627?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

Phase 2 Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids in Adult Subjects With Moderate to Severe Atopic Dermatitis

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis [Completed]

https://clinicaltrials.gov/ct2/show/NCT03575871?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Dermatitis, Atopic
Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
Sponsor:   Pfizer
Completed

CLINICALTRIALS.GOV IDENTIFIER:
NCT03575871

FIRST POSTED:
Tue, 03 Jul 2018 12:00:00 EDT

LAST UPDATE POSTED:
09/23/19 07:49AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03575871?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis [Suspended]

https://clinicaltrials.gov/ct2/show/NCT03245385?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Intervention:   Drug: Treatment with Halobetasol propionate 0.05% topical spray
Sponsors:   Sun Pharmaceutical Industries Limited;   Novum Pharmaceutical Research Services
Suspended

CLINICALTRIALS.GOV IDENTIFIER:
NCT03245385

FIRST POSTED:
Thu, 10 Aug 2017 12:00:00 EDT

LAST UPDATE POSTED:
09/23/19 07:49AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03245385?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F09%2F2019&lupd_d=14&sort=nwst

Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

DESCRIPTION:
Condition:   Atopic Dermatitis
Interventions:   Drug: ASLAN004;   Drug: ASLAN004 Placebo
Sponsor:   Aslan Pharmaceuticals
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04090229

FIRST POSTED:
Mon, 16 Sep 2019 12:00:00 EDT

LAST UPDATE POSTED:
09/21/19 11:41AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04090229?type=Intr&cond=Eczema&phase=0124&lupd_s=09%2F07%2F2019&lupd_d=14&sort=nwst

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream in Adult Subjects With Chronic Hand Eczema

https://clinicaltrials.gov/ct2/show/NCT03683719

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema
Actual Study Start Date : December 7, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Back to top